Compare Stocks: RCUS, IBRX, MDGL, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$9.81 +0.1%	$8.43	$1.95 ▼ $12.43	$10.45B	0.02	20.46 million shs	456,622 shs
MDGL Madrigal Pharmaceuticals	$470.81 +0.8%	$518.36	$393.61 ▼ $615.00	$10.75B	-1.04	331,944 shs	6,237 shs
PCVX Vaxcyte	$68.06 +1.9%	$60.67	$39.87 ▼ $90.75	$10.07B	1.23	1.58 million shs	20,735 shs
RCUS Arcus Biosciences	$23.18 +3.0%	$27.31	$15.38 ▼ $31.74	$2.97B	0.94	1.29 million shs	39,568 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	-3.16%	+1.14%	+23.89%	+26.78%	+295.16%
MDGL Madrigal Pharmaceuticals	-3.22%	-8.93%	-15.41%	-17.83%	+5.70%
PCVX Vaxcyte	-5.45%	+0.15%	+12.33%	+17.73%	+52.48%
RCUS Arcus Biosciences	-7.39%	-7.19%	-8.45%	-19.66%	+35.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$9.81 +0.1%	$8.43	$1.95 ▼ $12.43	$10.45B	0.02	20.46 million shs	456,622 shs
MDGL Madrigal Pharmaceuticals	$470.81 +0.8%	$518.36	$393.61 ▼ $615.00	$10.75B	-1.04	331,944 shs	6,237 shs
PCVX Vaxcyte	$68.06 +1.9%	$60.67	$39.87 ▼ $90.75	$10.07B	1.23	1.58 million shs	20,735 shs
RCUS Arcus Biosciences	$23.18 +3.0%	$27.31	$15.38 ▼ $31.74	$2.97B	0.94	1.29 million shs	39,568 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	-3.16%	+1.14%	+23.89%	+26.78%	+295.16%
MDGL Madrigal Pharmaceuticals	-3.22%	-8.93%	-15.41%	-17.83%	+5.70%
PCVX Vaxcyte	-5.45%	+0.15%	+12.33%	+17.73%	+52.48%
RCUS Arcus Biosciences	-7.39%	-7.19%	-8.45%	-19.66%	+35.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	44.90% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$710.20	57.08% Upside
PCVX Vaxcyte	2.67	Moderate Buy	$110.50	65.42% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	69.89% Upside

Current Analyst Ratings Breakdown

Latest RCUS, IBRX, MDGL, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	PCVX Vaxcyte	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$120.00
10/6/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/5/2026	PCVX Vaxcyte	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$116.00 ➝ $125.00
10/5/2026	PCVX Vaxcyte	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$89.00
10/5/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$110.00 ➝ $122.00
10/2/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$43.00
9/28/2026	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$133.00 ➝ $130.00
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/25/2026	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$704.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	91.68	N/A	N/A	($0.51) per share	-19.22
MDGL Madrigal Pharmaceuticals	$958.40M	10.90	N/A	N/A	$26.54 per share	17.04
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
RCUS Arcus Biosciences	$247M	11.62	N/A	N/A	$5.84 per share	3.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	81.46	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest RCUS, IBRX, MDGL, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8387	N/A	N/A	N/A	$404.72 million	N/A
11/3/2026	Q3 2026	PCVX Vaxcyte	-$2.11	N/A	N/A	N/A	$12.50 million	N/A
10/27/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8769	N/A	N/A	N/A	$11.14 million	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	5.72	5.70
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
PCVX Vaxcyte	N/A	5.72	5.72
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
MDGL Madrigal Pharmaceuticals	98.50%
PCVX Vaxcyte	96.78%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
MDGL Madrigal Pharmaceuticals	17.60%
PCVX Vaxcyte	3.30%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable
PCVX Vaxcyte	507	148.80 million	143.89 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

RCUS, IBRX, MDGL, and PCVX Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Now Covered by JPMorgan Chase & Co.

54 minutes ago | marketbeat.com

JPMorgan Starts Arcus Biosciences (RCUS) at Overweight

2 hours ago | streetinsider.com

JPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target

2 hours ago | marketscreener.comM

Arcus Biosciences (NYSE:RCUS) Shares Down 6.1% - Here's What Happened

October 13 at 1:39 PM | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants - October 9, 2026

October 12 at 1:19 PM | biospace.comB

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Has Average Price Target of $38.30

October 11 at 2:15 AM | americanbankingnews.com

Arcus Biosciences, Inc. (RCUS) - What Are Brokerages Thinking About This Stock?

October 11 at 2:13 AM | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

October 9, 2026 | businesswire.com

Arcus Biosciences Completes Early Cancer Trial for AB801, Setting Up Next Pipeline Moves

October 9, 2026 | tipranks.com

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?

October 7, 2026 | finance.yahoo.com

Arcus Biosciences stock fell 3.13 percent on October 2

October 6, 2026 | ad-hoc-news.deA

Arcus Biosciences stock gains 1.49 percent ahead of data event

October 6, 2026 | ad-hoc-news.deA

Wall Street Zen upgrades Arcus Biosciences stock to Hold

October 5, 2026 | ad-hoc-news.deA

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

October 4, 2026 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Raised to "Hold" at Wall Street Zen

October 3, 2026 | americanbankingnews.com

Arcus Biosciences (NYSE:RCUS) Stock Moved Up to Hold by Wall Street Zen

October 3, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Earns Outperform Rating from Wedbush

September 30, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants - September 24, 2026

September 25, 2026 | biospace.comB

Arcus Biosciences stock trades 16.8 percent below yearly high

September 24, 2026 | ad-hoc-news.deA

835,504 Shares in Arcus Biosciences, Inc. $RCUS Bought by Bank of America Corp DE

September 24, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading Up 3.2% - Should You Buy?

September 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCUS, IBRX, MDGL, and PCVX Company Descriptions

ImmunityBio NASDAQ:IBRX

$9.81 +0.01 (+0.06%)

As of 09:54 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$470.81 +3.65 (+0.78%)

As of 09:54 AM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Vaxcyte NASDAQ:PCVX

$68.06 +1.26 (+1.88%)

As of 09:54 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Arcus Biosciences NYSE:RCUS

$23.18 +0.67 (+2.95%)

As of 09:54 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, IBRX, MDGL, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, IBRX, MDGL, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, IBRX, MDGL, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCUS, IBRX, MDGL, and PCVX Company Descriptions

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Vaxcyte NASDAQ:PCVX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, IBRX, MDGL, and PCVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, IBRX, MDGL, and PCVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, IBRX, MDGL, and PCVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCUS, IBRX, MDGL, and PCVX Company Descriptions

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Vaxcyte NASDAQ:PCVX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools